Rese-cel one-time CAR T shows promising efficacy, safety profile
The therapy’s autoimmune-disease data point to strong efficacy and a differentiated safety profile, with pivotal results and a BLA filing expected next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.